30 closest matches · ranked by relevance
Anti-p53 TCR-Gene
Primary: Clinical Tumor Regression — 1 Participants
Ovarian Cancer
Primary: Adverse Events Related to Study Treatment — 5 Participants
Breast Cancer
Primary: Number of Participants Who Experienced Toxicity to the Vaccine — 0; 0 Participants
Melanoma · Skin Cancer
Primary: Clinical Tumor Regression. — 0; 0; 6; 0 Participants
Cervical Cancer · Renal Cancer · Urothelial Cancer
Primary: Maximum Tolerated Cell Dose (MTD) of Cluster of Differentiation 4 (CD4) Cells Transduced With an Anti-MAGE-A3-DP0401/0402 Restricted (MAGE-A3-DP4) T Cell Receptor and…
Multiple Myeloma
Primary: Adverse Events Related to Study Treatment — 24 participants
Melanoma · Meningioma · Breast Cancer
Primary: Percentage of Participants With a Response — 10; 50 percentage of participants
Melanoma · Advanced Melanoma
Primary: Number of Genes Predictive of Response at Baseline — 52 genes
Carcinoma, Squamous Cell · Head and Neck Neoplasms · Oropharyngeal Neoplasms
Primary: Progression Free Survival (PFS) — 3; 6; 0; 8 Participants
Pancreatic Cancer
Primary: Number of Patients With Treatment Related Serious Adverse Events — 0; 1; 0 Participants
Vaginal Cancer · Cervical Cancer · Anal Cancer
Primary: Maximum Tolerated Dose (MTD) — 2 # of cells x 10^11
Breast Cancer
Primary: The Number of Evaluable Patients With Complete Response or Partial Response or Stable Disease for ≥10 Weeks From the First Infusion (6 Weeks After the Second Infusion)…
Non-small Cell Lung Cancer Stage I
Primary: Examine the T-cell Receptor Profile Changes Induced in the Tumor After SABR
Malignant Glioma · Glioblastoma · Brain Cancer
Primary: Number of Treatment Related Adverse Events — 0; 0; 0; 0 adverse events
Papillomavirus Infections · Cervical Intraepithelial Neoplasia · Carcinoma In Situ
Primary: Phase II: Overall Response Rate Partial Response + Complete Response (PR +CR) — 0; 5 Participants
Ewing's Sarcoma · Rhabdomyosarcoma
Primary: Number of Participants With an Immune Response to Tumor-specific and Non-tumor Specific Peptides During a Period of Immune Reconstitution — 9; 23 Participants
Sarcoma
Primary: Incidence of Adverse Events Measured by the National Cancer Institute Common Terminology Criteria for Adverse Events Version (v)4.03 — 1; 1; 1; 1 participants
Primary Immune Deficiency Disorder · Hematopoietic Stem Cell Transplantation
Primary: Overall Survival — 86; 86; 87 percentage of survival probability — p=0.95
MDS
Primary: Complete Response Rate (CR) — 27; 17 Participants
Solid Tumor · Lymphoma · Peripheral T-Cell Lymphoma
Primary: Evaluate the Safety and Tolerability of ALRN-6924 in Adult Patients With Advanced Solid Tumors or Lymphomas With Wild-type (WT) TP53 Who Are Refractory to or Intolerant…
Cancer
Primary: Number of Participants and Type of Reported Adverse Events — 25; 22; 22; 6 Participants
Neoplasms
Primary: Objective Response Rate (ORR) — 50; 30.8; 20; 26.7 Percentage of Participants
Acute Myeloid Leukemia
Primary: Incidence of Adverse Events — 1; 1; 1; 1 participants
Multiple Myeloma
Primary: Fraction of Patients (n=3) for Whom a sdAb Could be Generated That Binds to the Idiotype of the Paraprotein. — 2 Participants
Colorectal Cancer Metastatic
Primary: Overall Response Rate — 0 participants
Prostate Cancer
Primary: Number of Participants With > = Grade 2 Autoimmune Events or >=Toxicities at Least Possibly Related to pTVG-HP With GM-CSF Study Treatment. — 1; 0 participants
Lymphoma, B-Cell · Lymphoma, Non-hodgkins
Primary: Percentage of Enrolled Participants Who Actually Get Treated — 76.9 percentage of participants
High-grade Serous Ovarian Cancer
Primary: Overall Response Rate (ORR) — 1; 0; 0; 0 Participants
Metastatic Non-small Cell Lung Cancer
Primary: Number of Participants With Adverse Events and/or Dose Limiting Toxicities as a Measure of Safety and Tolerability of Dose of PD-1 Knockout T Cells Using Common…
Melanoma
Primary: Disease Free Survival Assessment — 32; 30; 31; 30 Participants